SUMMARY
Inotropic support is often required to stabilize the hemodynamics of patients with acute decompensated heart failure; while efficacious, it has a history of leading to lethal arrhythmias and/or exacerbating contractile and energetic insufficiencies. Novel therapeutics that can improve contractility independent of beta-adrenergic and protein kinase A-regulated signaling, should be therapeutically beneficial. This study demonstrates that acute protein kinase C-a/b inhibition, with ruboxistaurin at 3 months' post-myocardial infarction, significantly increases contractility and reduces the end-diastolic/end-systolic volumes, documenting beneficial remodeling. These data suggest that ruboxistaurin represents a potential novel therapeutic for heart failure patients, as a moderate (4) . However, these drugs can induce lethal arrhythmias (5) , and because they can also cause Ca 2þ overload in the sarcoplasmic reticulum (SR), they can induce myocyte death (6) and thereby exacerbate HF progression. Therefore, patients that survive episodes of ADHF that required the use of PKA-activating inotropic support, have a worse prognosis (7) . Novel inotropic therapies that increase cardiac contractility and have positive effects on ventricular remodeling, but avoiding PKA signaling, could help patients with HF.
Over the last decade, we (8) (9) (10) (11) (12) ) and others (13) (14) (15) (16) (17) have investigated the role of protein kinase C (PKC)
in the alterations of basal inotropy and inotropic reserve in small-animal HF models. PKC is a family of serine/threonine protein kinases, which are activated through Ca 2þ -and/or lipid-mediated signaling mechanisms, and are enhanced in HF. The major PKC isoform expressed in cardiac tissue of small (mouse) (18) and large (rabbit) (19) animals, as well as in humans, is PKCa (12). PKCa abundance and activity increases in the diseased heart and has been linked to reduced cardiac myocyte contractility, whereas PKCa inhibition increases cardiac contractility (10) . PKCatarget proteins are distinct from those activated by PKA (4, 20) and include classical Ca 2þ handling and regulator proteins within the membrane, cytosol, and at the level of sarcomeric proteins (10, (15) (16) (17) 21) .
Studies performed largely in mouse models suggest that inhibition of PKCa could be a PKA-independent approach to increase contractility in the failing human heart (9, 10 Sharp III et al.
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given set of pressures to observe curve shifts in the ESPVR and EDPVR. Sharp III et al.
Ruboxistaurin Improves Cardiac Function in Experimental HFrEF (G) Animals underwent sham (n ¼ 6) or MI (n ¼ 6) procedure, and terminal studies were performed at 3 months AE PMI. Tissue was collected for molecular analysis. Protein was isolated and fractionated into cytosolic (C) and membrane (M) fractions. Percentage of membrane-bound fraction over the cytosolic fraction is shown. *p # 0.05; ***p # 0.005 versus sham. Large scale bar ¼ 100 mm. Small scale bar ¼ 50 mm.
3 months PMI ¼ 3-month's post-myocardial infarction; other abbreviations as in Figure 1 .
Sharp III et al. Table 1 ). LV pressure and volume measurements showed that the EDPVR was shifted to larger volumes at spontaneous heart rates ( Figures 4A and 4B ). The LV volume at an end-diastolic pressure of 10 mm Hg (LVVPed10) was also increased, confirming dilation ( Figure 4D ). EF was found to be significantly reduced versus baseline Sharp III et al.
showing a decreased amount of work being performed for a given volume. There was also widening of the QRS complex at 3 months post-MI, suggesting electrical remodeling, likely due to scar formation and diffuse fibrosis within the remote zone (Supplemental Table 2 ). These functional data confirmed the development of a HFrEF phenotype in these animals at 3 months post-MI.
DOB's EFFECTS 3 MONTHS POST-MI ARE REDUCED.
Cardiac inotropic responses to DOB (2.5 mg/kg/min)
were measured before and 3 months after MI ( Figure 5 , Supplemental Table 1 ). This DOB concentration was chosen because it produced a doubling of the dP/dT max at baseline (30) . DOB infusion caused significant changes in ESPVR (specifically the E es ), LVVPes80, and dP/dTmax in the normal heart (Figures 5C, 5F, and 5H, Supplemental Table 1 ). DOB infusions performed at baseline were repeated in the same animals 3 months after MI. At 3 months post-MI, the overall DOB effects were reduced and only caused significant changes in dP/dTmax and PRSW (Supplemental Table 1 Echocardiography measurements also showed that RBX had no significant effect on cardiac filling volumes or LVEF in age-matched controls ( Figures 6D to   6F ). The significant reduction in EDVs and ESVs in MI þ RBX was confirmed with invasive hemodynamics (Supplemental Table 1 ). These studies showed a significant leftward shift in the pressure-volume loop, EDPVR, and LVVPed10 ( Figures 7A, 7B , and 7E). 
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In the presence of RBX treatment, the ESPVR and the load-independent measure, PRSW, shifted significantly leftward back toward baseline, whereas the LVVPes80 was substantially reduced ( Figures 7C, 7D , and 7F), demonstrating an increase in force of contraction. Although the marginal increase in E es was not significant versus 3 months PMI þ DOB, the V 0 was significantly reduced (Figures 7H and 7I ).
ECG measurements were made in RBX-treated animals. RBX increased the heart rate, but there were no other statistically significant alterations in ECG intervals (Supplemental Table 2 ). In control swine, RBX had no statistically significant effects on cardiac function ( Figures 6D to 6F ) or on rate, rhythm, or conduction (Supplemental Table 2 Sharp III et al. Activation of PKCa is known to reduce cardiac contractility in rodents (10,12). PKCa activity is and phosphorylation sites, serine 16 (S16) and threonine 17 (T17). RBX had no effect on the S16 or T17 phosphorylation. †p # 0.05 versus 3 months PMI. Abbreviations as in Figures 1, 2, 4 , and 5.
Sharp III et al. RBX had no significant effects in normal animals.
These results are consistent with the idea that PKCa activity increases in MI heart, and this contributes to the depressed contractility. Our results suggest that these contractility defects can be reversed with PKCa antagonism, consistent with related studies in rodents and other large animals (8) (9) (10) (11) (12) 24) . 
CONCLUSIONS
Our results demonstrate that RBX significantly increases cardiac function in an IR/MI model of HFrEF.
RBX had no statistically significant inotropic or EDV-modifying effects in normal swine, consistent with our finding that PKCa activity is lower in the normal heart and increases with disease progression.
Others have found that PKCa activity increases in proportion to disease burden (33, 56 Sharp III et al.
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